Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Nuvation Bio (NUVB) EBITDA (2023 - 2025)

Nuvation Bio (NUVB) has disclosed EBITDA for 3 consecutive years, with -$36.6 million as the latest value for Q4 2025.

  • On a quarterly basis, EBITDA rose 27.09% to -$36.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$205.4 million, a 63.81% increase, with the full-year FY2025 number at -$205.4 million, up 63.81% from a year prior.
  • EBITDA was -$36.6 million for Q4 2025 at Nuvation Bio, up from -$55.6 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of -$10.3 million in Q4 2023 to a low of -$462.6 million in Q2 2024.
  • A 3-year average of -$70.3 million and a median of -$37.6 million in 2024 define the central range for EBITDA.
  • Peak YoY movement for EBITDA: tumbled 1993.45% in 2024, then skyrocketed 87.06% in 2025.
  • Nuvation Bio's EBITDA stood at -$10.3 million in 2023, then plummeted by 387.51% to -$50.3 million in 2024, then increased by 27.09% to -$36.6 million in 2025.
  • Per Business Quant, the three most recent readings for NUVB's EBITDA are -$36.6 million (Q4 2025), -$55.6 million (Q3 2025), and -$59.9 million (Q2 2025).